Uri Geiger
Founder & Managing Partner @ Accelmed
Uri Geiger is a funding round investor at Accelmed focused on Health Care and Medical Device. Dr. Geiger brings extensive entrepreneurial, management and investment know-how creating and building many successful businesses. Dr. Geiger co-founded Accelmed together with Mori Arkin in 2009 with the goal of forming a leading investment company solely dedicated to the medical device industry. Until January 2009, Dr. Geiger served as theCEO of Exalenz Bioscience Ltd. (TASE:EXEN), developer of an innovative breath-based technology for diagnosing liver and gastrointestinal disorders that he acquired from Oridion Systems (today part of Covidien) and took public in 2007. He previously co-founded and was the CEO of GalayOr Networks, a developer of optical components which was sold in 2003 to MEMSCAP (EuroNext: MEMS). Dr. Geiger is also the founding partner of Dragon Variation Fund, one of Israel's first hedge funds which was sold to Migdal in 2007. Prior to returning to Israel in 1999, Dr. Geiger gained a broad understanding and experience in capital markets working on Wall-street during the 1990s.Dr. Geiger was formerly an adjunct professor at Tel Aviv University's Recanati School of Business where he lectured on private equity and venture capital and he is the author of the books "Startup Companies and Venture Capital" (Tel Aviv University Press, 2001) and "From Concept to Wall Street" (Financial Times - Prentice Hall, 2003). He earned his doctorate from New York's Columbia University Center for Law & Economics, with a concentration in global equity markets. Dr. Geiger served as a major (Ret.) in the Israeli Air force.
- Total investments:
- 16
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Uri Geiger invests in
Stages Uri Geiger invests in
Countries Uri Geiger invests in
Investment Focus
Industry
- Health Care 11 (69%)
- Medical Device 8 (50%)
- Medical 3 (19%)
- Biotechnology 3 (19%)
- Manufacturing 3 (19%)
Stage
- Funding Round 4 (25%)
- Series D 2 (13%)
- Post-IPO Equity 2 (13%)
- Venture - Series Unknown 2 (13%)
- Series B 1 (6%)
Country
- United States 8 (50%)
- Israel 3 (19%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Minerva Surgical
|
Minerva Surgical is a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women. The company has established a broad product line of commercially available, minimally invasive alternatives to hysterectomy, which aredesigned to address the most common causes of abnormal uterine bleeding (AUB) in most uterine anatomies. The Minerva Surgical solutions can be used in a variety of medical treatment settings and aim to address the drawbacks associated with alternative treatment methods and to preserve the uterus by avoiding unnecessary hysterectomies. | $30M / Post-IPO Equity / Dec 27, 2022 | |
MedMinder Systems
|
MedMinder Systems provides services that simplify medication management and improve medication adherence. It offers an automatic pill dispenser that reminds users when it is time to take their medication through flashes, beeps, text messages, and phone calls. It also provides the user's caregivers, family members, or pharmacists withnotifications about their dosage activity, which can be monitored remotely through a patient profile on MedMinder's website.The company was founded in 2007 and is headquartered in Needham, Massachusetts. | $25M / Debt Financing / Aug 30, 2022 | |
|
MedMinder Systems
|
MedMinder Systems provides services that simplify medication management and improve medication adherence. It offers an automatic pill dispenser that reminds users when it is time to take their medication through flashes, beeps, text messages, and phone calls. It also provides the user's caregivers, family members, or pharmacists withnotifications about their dosage activity, which can be monitored remotely through a patient profile on MedMinder's website.The company was founded in 2007 and is headquartered in Needham, Massachusetts. | $10M / Venture - Series Unknown / Aug 24, 2022 | |
Veranex
|
Veranex is the first truly end-to-end, global, tech-enabled, concept-through-commercialization service provider that focuses solely on medical technology: medical device, diagnostics, companion diagnostics, digital health, and drug delivery. For all your needs through the entire medical device clinical trial process, Veranex is transforming medtechinnovations. | Private Equity / May 19, 2022 | |
Click Therapeutics
|
Click Therapeutics develops and commercializes software as medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive datascience platform continuously personalizes user experience to optimize engagement and outcomes. Following a groundbreaking clinical trial, Click’s industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click’s lead prescription program is entering into a multi-center, randomized, controlled, parallel-group, phase III FDA registration trial for the treatment of Major Depressive Disorder in adults. | $52M / Series B / Oct 22, 2021 | |
Keystone Dental
|
Keystone Dental was founded in March 2006, and aspires to build a market leading, global brand recognized within the dental community for its integrity, trust and commitment to improving the standard of care for patients and their quality of life. Since then, they have rapidly grown into a diversely skilled, fast-moving team of professionalscommitted to providing excellent customer service and producing high-quality products and services. | $25M / Venture - Series Unknown / Sep 01, 2021 | |
EndoGastric Solutions
|
EndoGastric Solutions, Inc. (www.endogastricsolutions.com), is a medical device company developing and commercializing innovative, evidence-based, incisionless surgical technology for the treatment of GERD. EGS has combined the most advanced concepts in gastroenterology and surgery to develop the Transoral Incisionless Fundoplication (TIF®) 2.0procedure—a minimally invasive solution that addresses a significant unmet clinical need.EndoGastric Solutions, Inc. was founded in 2003 and is headquartered in Redmond, Washington. | $15M / Series I / May 28, 2019 | |
Strata Skin Sciences
|
Strata Skin Sciences is a medical technology company that specializes in dermatology and plastic surgery. Its products include the XTRAC® laser and VTRAC® excimer lamp systems utilized in the treatment of psoriasis, vitiligo, and various other skin conditions; and the MelaFind® system used to assist in the identification and management of melanomaskin cancer. | $17M / Post-IPO Equity / Apr 02, 2018 | |
EndoChoice
|
EndoChoice is a medtech company focused on the manufacturing and commercialization of platform technologies including devices, diagnostics, infection control and endoscopic imaging for specialists treating a wide range of gastrointestinal (GI) diseases. EndoChoice leverages its direct sales organization to serve more than 2,000 customers in theUnited States and works with 34 distribution partners world-wide. The Company was founded in 2008 and has rapidly developed a proprietary product portfolio, which includes the revolutionary Full Spectrum Endoscopy™ System (Fuse™). The Fuse System is comprised of colonoscopes and gastroscopes with multiple imagers so doctors can see more of the GI tract for diagnosis and treatment. The Fuse colonoscope provides a field of view of 330 degrees versus 170 degrees from traditional endoscopes. In clinical studies, Fuse found 70% more polyps than traditional colonoscopies. 2013 marked the fourth consecutive year EndoChoice was recognized as one of the fastest growing companies in the U.S. by Inc. Magazine. To learn more, visit www.endochoice.com | $57M / Series D / Mar 05, 2015 | |
CartiHeal
|
CartiHeal, a privately held medical device company headquartered in Israel, is a pioneer in the field of cartilage regeneration. Cartilage injuries affect millions of patients around the world, and characteristically cause severe pain and disability. Hyaline cartilage has a very limited ability to heal once damaged. Research indicates that injuriesto joint cartilage, if left untreated, may lead to progressive joint changes and early onset of osteoarthritis. The need for a simple, well-tolerated and effective solution for cartilage repair and regeneration represents one of medicine’s most challenging unmet needs. CartiHeal's flagship Agili-C™ implant represents a significant medical breakthrough. This implant has shown to promote regeneration of true hyaline cartilage and its subchondral bone, simultaneously without the use of cells, growth factors or other exogenous agents. The cell-free implant is inserted arthroscopically or via a minimally-invasive approach. | Oct 29, 2013 | |
| See all 16 investments → | |||
Co-Investors
About Accelmed
Accelmed is a venture capital firm that funds private and public medical device companies with significant market potential and proven clinical data.Concentrating on medical device companies that have already reached the revenue stage enables the firm to assist companies in benefiting from its managerial capabilities and financial resources.Together with the management teams of their portfolio companies, the Accelmed can steer the way from the clinical-stage to a profitable business with a clear commercial plan, thereby accelerating the path to a successful exit.In 2009, Mori Arkin and Uri Geiger, the co-founders of Accelmed, established the firm in Herzliya, Tel Aviv.
Accelmed Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Gilad Rotem
Medical Analyst
|
|||
Lior Shav
Private Equity Investment Manager
|
|||
Michal Fisher
IP Consultant
|
|||
|
Uri Geiger
Founder & Managing Partner
|
|||
Camilo Rico
Vice President
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Uri Geiger invest in?
Uri Geiger invests primarily in Health Care, Medical Device and Medical startups, most often at Funding Round and Series D stage. Most of the 16 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Uri Geiger last invest?
The most recent investment recorded for Uri Geiger closed in Dec 2022. Shizune tracks 16 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
